XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.6700
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.6700
Open4.5800
Bid4.4500 x 800
Ask4.9000 x 1800
Day's Range4.4800 - 4.7800
52 Week Range3.9500 - 19.9400
Volume1,717,386
Avg. Volume2,969,309
Market Cap753.145M
Beta (3Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-3.8570
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • GuruFocus.com4 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $5.5 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 1,257,727 shares of XON on 05/15/2019 at an average price of $4.4 a share.

  • PR Newswire7 days ago

    Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

    GERMANTOWN, Md., May 13, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time. Mr. Kirk will focus on Intrexon Health's development of targeted, controllable, multigenic therapeutics for the treatment of complex diseases and unmet medical needs, highlighting the therapeutic candidates currently in clinical development. A live webcast of the presentation will be available on the Investors section of Intrexon's website at https://investors.dna.com/events, and a replay of the webcast will be available for 30 days following the event.

  • Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
    Zacks10 days ago

    Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

    Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

  • PR Newswire11 days ago

    Intrexon Reports First Quarter 2019 Financial Results

    GERMANTOWN, Md., May 9, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results for 2019. Intrexon announced alignment of its operations into two units, Intrexon Health and Intrexon Bioengineering, to better deploy resources, realize inherent synergies and position the company for growth with a core focus on healthcare.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for XON with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on April 25. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding XON totaled $821 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire18 days ago

    AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update

    MAYNARD, Mass., May 02, 2019 -- AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • PR Newswire18 days ago

    Intrexon to Release First Quarter 2019 Financial Results on May 9th

    GERMANTOWN, Md. , May 2, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • Here’s What Hedge Funds Think Of Intrexon Corp (XON)
    Insider Monkey18 days ago

    Here’s What Hedge Funds Think Of Intrexon Corp (XON)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for
    Zacks18 days ago

    Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for

    Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire21 days ago

    Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting

    GERMANTOWN, Md. , April 29, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland
    PR Newswire25 days ago

    Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland

    -Nearly 5,000 square foot facility will manufacture early stage clinical trial material for gene therapy trials GERMANTOWN, Md. , April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary ...

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares

    MAYNARD, Mass., April 17, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
    Zackslast month

    Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

    Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

  • PR Newswirelast month

    Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper

    Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries OXFORD, England , April 16, 2019 /PRNewswire/ -- Oxitec ...

  • GlobeNewswirelast month

    Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

    Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). “We are proud to partner with Castle Creek Pharmaceuticals, a company recognized for its innovation in drug development for rare skin diseases and its commitment to the epidermolysis bullosa community.

  • PR Newswirelast month

    Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference

    GERMANTOWN, Md. , April 10, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock

    MAYNARD, Mass., April 09, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development
    PR Newswirelast month

    Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development

    OXFORD, England, April 9, 2019 /PRNewswire/ -- Oxitec Ltd., a wholly-owned subsidiary of Intrexon (XON), today announced it has entered into a second agreement with a collaborator to advance the next phase of development of its self-limiting fall armyworm control solution. This announcement comes after the successful conclusion of an initial three-year research and development collaboration that funded the early development of the self-limiting fall armyworm strain.

  • Why Intrexon Stock Dropped 34% in March
    Motley Foollast month

    Why Intrexon Stock Dropped 34% in March

    Investors weren't happy to learn about its worsening cash position.

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock

    MAYNARD, Mass., April 04, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), today announced that it has commenced a proposed underwritten public offering of common stock of the Company. In addition, the Company expects to grant the underwriter of the offering a 45-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • PR Newswire2 months ago

    Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management

    - Move prompted by rapid progress at Intrexon's Precigen subsidiary - - Two therapeutic candidates from Precigen's game-changing UltraCAR-T™ therapeutic platform commencing clinical studies - GERMANTOWN, ...

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces that Environment and Climate Change Canada (ECCC) has approved the Company’s Rollo Bay production facility for the commercial manufacture and grow-out of AquAdvantage Salmon. After an extensive and thorough evaluation, ECCC approved the production of AquAdvantage Salmon at the site based on the physical, biological, and operational measures in place or planned at the Rollo Bay facility.

  • Why Is Intrexon (XON) Down 34% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Intrexon (XON) Down 34% Since Last Earnings Report?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.